- Home
- RDI vs PULM Comparison
RDI vs PULM Comparison
Compare RDI & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDI
- PULM
- Stock Information
- Founded
- RDI 1937
- PULM 2003
- Country
- RDI United States
- PULM United States
- Employees
- RDI N/A
- PULM N/A
- Industry
- RDI Movies/Entertainment
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- RDI Consumer Discretionary
- PULM Health Care
- Exchange
- RDI Nasdaq
- PULM Nasdaq
- Market Cap
- RDI 27.9M
- PULM 33.2M
- IPO Year
- RDI N/A
- PULM N/A
- Fundamental
- Price
- RDI $1.34
- PULM $6.41
- Analyst Decision
- RDI Hold
- PULM
- Analyst Count
- RDI 1
- PULM 0
- Target Price
- RDI $2.40
- PULM N/A
- AVG Volume (30 Days)
- RDI 27.4K
- PULM 57.7K
- Earning Date
- RDI 08-13-2025
- PULM 08-12-2025
- Dividend Yield
- RDI N/A
- PULM N/A
- EPS Growth
- RDI N/A
- PULM N/A
- EPS
- RDI N/A
- PULM N/A
- Revenue
- RDI $205,644,000.00
- PULM $1,921,000.00
- Revenue This Year
- RDI $7.47
- PULM N/A
- Revenue Next Year
- RDI $13.22
- PULM $134.88
- P/E Ratio
- RDI N/A
- PULM N/A
- Revenue Growth
- RDI N/A
- PULM N/A
- 52 Week Low
- RDI $1.17
- PULM $1.78
- 52 Week High
- RDI $1.89
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- RDI 53.00
- PULM 37.18
- Support Level
- RDI $1.27
- PULM $6.28
- Resistance Level
- RDI $1.34
- PULM $6.83
- Average True Range (ATR)
- RDI 0.06
- PULM 0.35
- MACD
- RDI 0.01
- PULM -0.07
- Stochastic Oscillator
- RDI 87.50
- PULM 0.00
About RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).